GRAFORCE
15.5.2023 02:01:27 CEST | Business Wire | Press release
Graforce, Germany’s leading provider of zero carbon hydrogen plants, and Worley, a leading global engineering and project delivery business, are cooperating to scale methane electrolysis (plasmalysis) starting in Australia, Pacific, Asia and China. Plasmalysis is a game changing technology, which converts natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting CO2 or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or mode of transportation. Graforce and Worley will present plasmalysis plants at APPEA 2023 in Adelaide, Australia (15-18 May) at the Worley sponsored Hydrogen Pavilion showcasing latest innovations in the hydrogen industry and its impact on decarbonization of industries and fossil fuels.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005004/en/
Methane Plasmalysis plants – graphics shows a 12 MW plant - convert natural gas, LNG, flare gas and other hydrocarbons into hydrogen without emitting carbon dioxide or any other greenhouse gas into the atmosphere. This allows gas consumers to switch to clean-burning hydrogen without changing their energy supplier or way of transportation. (Graphic: Business Wire)
Australia is among the largest producers of natural gas and one of the world's leading fuel suppliers. Projects to supply Germany with LNG and green hydrogen are in progress. At the same time, the country aims to reduce its CO2 emissions by more than 40 percent by 2030. Sustainable technologies like plasmalysis are an essential requirement to meet both, economic and climate targets.
“The entire APAC region is looking for green technologies for existing energy sources to achieve climate targets. The cooperation with Worley is an important step for us to quickly scale our methane plasmalysis and to open up these markets,” said Dr. Jens Hanke, CTO of Graforce.
Worley provides large scale engineering, procurement, and construction services to the energy, resources, and chemicals industries. Worley will provide engineering and project delivery services for plasmalysis plants customers in Australia and Asia. In the modular plants, a high-frequency plasma field generated by renewable electricity splits hydrocarbons such as methane into their molecular components: hydrogen and solid carbon. Compared to water electrolysis, plasmalysis requires only one-fifth the energy to produce the same amount of hydrogen. A single 20-megawatt plant can convert about 70,000 metric tons of methane into hydrogen per year and eliminate about 200,000 metric tons of CO2 emissions.
“As we scale up towards the vast quantities of renewable energy and hydrogen required to meet our Net Zero goals, our medium-term reliance on fossil fuels and in particular, natural gas and LNG, is a given. Plasmalysis marries these two realities together and enables faster decarbonisation utilising existing infrastructure. Plasmalysis is likely to be a valuable tool in the decarbonisation toolbox and contribute to our company purpose of delivering a more sustainable world,” says Gillian Cagney, Worley ANZ Managing Director.
About
Graforce is a German hydrogen technology company. Their power-to-X plants produce carbon dioxide free or carbon dioxide negative hydrogen and synthetic feedstocks – with highest efficiency and lower infrastructure costs in the multi-megawatt range. Thus, Graforce decarbonizes fossil energies, industries and the heat, transport and building sectors. Graforce is currently in the process of expanding its financial and strategic partnerships to quickly scale its hydrogen technology worldwide.
Worley is a global company headquartered in Australia and our purpose is delivering a more sustainable world. Worley is a leading global provider of professional project and asset services in the energy, chemicals and resources sectors. As a knowledge-based service provider, we use our knowledge and capabilities to support our customers to reduce their emissions and move towards a low carbon future. Worley Limited is listed on the Australian Securities Exchange (ASX: WOR).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
